B7-H3 silencing inhibits tumor progression of mantle cell lymphoma and enhances chemosensitivity

WEI ZHANG, YANFANG WANG, JING WANG, FEI DONG, MINGXIA ZHU, WENLI WAN, HAISHEN LI, FEIFEI WU, XINXING YAN and XIAOYAN KE

Department of Hematology and Lymphoma Research Center, Peking University Third Hospital, Beijing 100191, P.R. China

Received February 2, 2015; Accepted March 27, 2015

DOI: 10.3892/ijo.2015.2962

Abstract. B7-H3 (CD276), known as a member of B7 immunoregulatory family, is a type I transmembrane glycoprotein aberrantly expressed in numerous types of cancer and associated with poor prognosis. However, the role of B7-H3 in oncogenesis and chemosensitivity of mantle cell lymphoma (MCL) remains unknown. We determined the effects of downregulating B7-H3 expression on tumor progression and the sensitivity of chemotherapeutic drug in mantle cell lymphoma. B7-H3 knockdown was performed using lentivirus transduction in the Maver and Z138 mantle cell lymphoma cell lines, respectively. The effects of B7-H3 on cell proliferation, cycle, migration and invasion were investigated by CCK-8 assay, methyl cellulose colony forming assay, PI staining, and Transwell assays in vitro. By establishing Maver and Z138 xenograft models, the effects of B7-H3 on tumorigenicity were observed, and Ki-67 and PCNA was detected by immunohistochemistry. The downregulation of B7-H3 significantly decreased tumor proliferation in MCL in vitro and in vivo. In the B7-H3 knockdown groups of Maver and Z138 xenograft models, the mean inhibition rate of tumor growth was 59.1 and 65.0% (p=0.010 and 0.003), and the expression of both Ki-67 and PCNA were significantly lower, respectively. After B7-H3 silencing, the cell cycles of Maver and Z138 were both arrested at G0/G1 phase, and the cell migration rates and invasion capacity were decreased as well. Moreover, the impacts of B7-H3 RNAi on the antitumor effect of chemotherapy drugs were determined with CCK-8 and Annexin V-FITC/PI assays in vitro and with xenograft models in vivo. The silencing of B7-H3 increased the sensitivity of Maver and Z138 cells to rituximab and bendamustine and enhanced the drug-induced apoptosis, respectively. Our study demonstrates for the first time that B7-H3 promotes mantle cell lymphoma progression and B7-H3 knockdown significantly enhances the chemosensitivity. This may provide a new therapeutic approach to mantle cell lymphoma.

Introduction

Mantle cell lymphoma (MCL), a heterogeneous subtype of B-cell non-Hodgkin lymphoma (NHL), accounts for ~7% of NHL cases in the USA and Europe and has one of the worst outcomes of all the lymphomas (1,2). It is characterized by the t(11;14) (q13;q32) translocation, which results in overexpression of cyclin D1 and deregulation of the cell cycle (2). At initial diagnosis, most patients with the median age ~68-70 years have advanced stage disease, and the median overall survival is 3-5 years (3). Although several novel agents have proven to be effective, MCL remains a largely incurable disease and the following relapse is still challenging. Therefore, understanding the molecular mechanisms of MCL pathogenesis and drug resistance will aid in the development of highly active targeted therapies for the disease.

B7-H3, a new member of B7 immunoregulatory family with immunoglobulin-like structure (4), is induced in activated dendritic cells, monocytes and T cells (5). Aberrant expression of B7-H3 has been reported and associated with poor prognosis in patients with neuroblastoma (6), lung cancer (7), pancreatic cancer (8), colorectal cancer (9), hepatocellular carcinoma (10) and breast cancer (11). In hematologic malignancy, the overexpression of B7-H3 also has been described, including acute leukemia (12), multiple myeloma (13) and several types of lymphoma (14).

The physiological and pathological role of B7-H3 remains contentious, with stimulatory (4,15,16) and inhibitory (17-19) immunoregulatory functions in cellular and antitumor immune response described in early studies. Currently, the non-immunological functions of B7-H3 in cancer progression and chemoresistance have received increasing attention. Tekle et al demonstrated that the B7-H3 silencing reduced metastatic capacity of MDA-MB-435 melanoma cells and significantly increased the survival of nude mice (20). Other studies also reported that B7-H3 was important in regulating the adhesive, migratory, and invasive capacity in breast cancer (21), glioblastoma (22), pancreatic cancer (23), prostate cancer (24) and osteosarcoma (25). Liu et al discovered that silencing

Correspondence to: Dr Xiaoyan Ke, Department of Hematology and Lymphoma Research Center, Peking University Third Hospital, 49 North Garden Road, Haidian District, Beijing 100191, P.R. China E-mail: xykbysy@163.com

Abbreviations: MCL, mantle cell lymphoma; NHL, non-Hodgkin lymphoma; FBS, fetal bovine serum

Key words: B7-H3, mantle cell lymphoma, cancer gene therapy, chemosensitivity
of B7-H3 sensitized the breast cancer cell lines to paclitaxel by abrogating Jak2/Stat3 phosphorylation (26). In pancreatic carcinoma cells, B7-H3 was demonstrated to induce gemcitabine resistance as well (27). The above research indicated that B7-H3 may be a potential therapeutic target.

However, little is known about the direct impact of B7-H3 on tumor progression and B7-H3 RNAi-based targeting therapy in MCL. In this study, we investigated the role of B7-H3 in mantle cell lymphoma Maver and Z138 cell proliferation, the cell cycle, migration, invasion and in the chemosensitivity in vitro and in vivo.

Materials and methods

Cell line and cell culture. Human mantle cell lymphoma Maver and Z138 cell lines were obtained from the American Type Culture Collection (ATCC, Rockville, MD, USA). The cells were, respectively cultured in Iscove's modified Dulbecco's medium (IMDM) and RPMI-1640 (Gibco Invitrogen, Grand Island, NY, USA) medium containing 2 mM L-glutamine, 100 U/ml penicillin, 100 µg/ml streptomycin and 10% heat-inactivated fetal bovine serum (FBS) (Thermo Scientific HyClone, South Logan, UT, USA), at 37°C in a 5% CO₂ incubator.

Lentivirus-based RNA interference transfection and generation of stable cell lines. The human B7-H3 (Gene ID: 80381) targeting small hairpin RNA (shRNA) sequence 5'-TCGTT TGCTGGAGAAAGATCAAACAGAGC-3' and a negative non-targeted control sequence 5'-GCACCTACAGAGCTA TCTAGATAGTACT-3' were used to generate recombinant lentiviral particles (20). These recombinent lentivirus were prepared and titrated to 5x10⁹ TU/ml (transfection unit), and the lentiviral particles (20) from eBioscience (San Diego, CA, USA) and CD3-APC, CD19-APC, CD117-APC, CD20-FITC, CD10-PE, CD5-PE, CD38-FTC, CD56-PE, CD138-APC, CD34-PE, CD45-PerCP, and appropriate isotype controls from BD Biosciences.

Gene expression of B7-H3. RT-PCR, western blotting and flow cytometry. Total RNA was extracted and reverse transcribed for cDNA. The primers used for PCR were as follows: 5′-CTCTG TGCTGGAGAAAGATCAAACAGAGC-3′ (forward) and 5′-CGACCTACAGAGCTACTTCTAGATAGTACT-3′ (reverse) for B7-H3 (134 bp) (23); 5′-TTGAGGAGGAGGACTC-3′ (forward) and 5′-ACTT GCAGTACTCCCTCCATG-3′ (reverse) for matrix metalloproteinase-2 (MMP-2, 153 bp); 5′-TTGACGGCAGCAAGAG TGG-3′ (forward) and 5′-CCCTCTCAATGAGGGTCATATAT-3′ (reverse) for matrix metalloproteinase-9 (MMP-9, 148 bp) (28) and 5′-TGACGGCAGCATCCGGCAAAGG-3′ (forward) and 5′-CTGAGGATGTTGAGCATAGAC-3′ (reverse) for β-actin (205 bp). The PCR conditions were 94°C for 2 min, then 28-36 cycles (B7-H3/MMP-2/MMP-9: 36 cycles; β-actin: 28 cycles) at 94°C for 30 sec, 56-59°C (B7-H3: 56°C; MMP-2/ MMP-9/β-actin: 59°C) for 30 sec, 72°C for 30 sec, and finally 72°C for 2 min.

The cells were lysed on ice, and the concentration of protein was determined using the BCA method. A total of 30 µg proteins were transferred onto nitrocellulose filter (NC) membranes after 10% SDS-PAGE. The membranes were blocked and incubated with primary antibodies, including rabbit anti-B7-H3 (1:500 dilution, 110 kDa) (clone EPNCIR122; Epitomics, Burlingame, CA, USA) or mouse anti-β-actin (1:1,000 dilution, 43 kDa) (clone C-2; Santa Cruz, CA, USA) monoclonal antibodies overnight at 4°C. After incubation with IRDye 800CW conjugated goat (polyclonal) anti-rabbit/anti-mouse IgG secondary antibody (1:10,000 dilution) (LI-COR, NE, USA) for 1 h, the fluorescent bands was visualized with an Odyssey infrared imaging system (LI-COR), and the gray values were analyzed using Odyssey V3.0 software.

Single cell suspensions were stained with antibodies on ice for 30 min. After three washes in PBS, the cells were analyzed using a flow cytometry system (FACSCalibur; BD Biosciences, San Jose, CA, USA). The monoclonal antibodies used to measure the expression of the cell surface markers by flow cytometry included B7-H3 (CD276)-APC (clone 7-517) from eBioscience (San Diego, CA, USA) and CD3-APC, CD19-APC, CD117-APC, CD20-FITC, CD10-PE, CD5-PE, CD38-FTC, CD56-PE, CD138-APC, CD34-PE, CD45-PerCP, and appropriate isotype controls from BD Biosciences.

CCK-8 assay. The Cell Counting Kit-8 (CCK-8; Dojindo Molecular Technologies, Tokyo, Japan) was used to study the effects of B7-H3 shRNA on cell proliferation. Resuspended cells were plated at 5x10⁴ cells/well in a 96-well plate for 24-, 48- or 72-h inoculation. A volume of 10 µl/well of CCK-8 solution was added into the plate. After incubation at 37°C for 5 h, the absorbance was measured at 450 nm using a microplate reader. The assay was performed in sextuplicate for each group.

Colony forming assay. A 5x10⁴ single-cell suspension was resuspended in 1 ml medium with 20% FBS and 0.9% methyl cellulose (Sigma, St. Louis, MO, USA). The samples were plated in 24-well plates and incubated for 14 days. A colony with >50 cells was counted as one positive colony. The colony-forming ability (CFA) = (colonies counts in experiment group/ control group) x 100%. Each experiment was repeated three times.

Subcutaneous xenograft model and tumorigenicity assay. Female BALB/c nude mice, 5-6 weeks of age, 16-18 g of weight (Experimental Animal Center, Peking University Health Science Center, Beijing, China), were bred under specified pathogen-free (SPF) conditions. All of the care, experimental procedures and handling of animals were performed with approval of the Institutional Authority for Laboratory Animal Care of Peking University. Mice were pretreated by intraperitoneal (i.p.) injection, with 100 mg/kg cyclophosphamide (Jiangsu Hengrui Medicine Co., Ltd., China) once daily for two consecutive days. The next day, 2x10⁷ cells (the Maver and Z138 cells in CON, NC or KD group respectively, 6 mice per group) in 100 µl normal saline (NS) were injected subcutaneously (i.c) into right axilla region of the nude mice.

The xenografted tumor volume (V) was measured every other day and calculated as: V (mm³) = length x width² x 0.5.
The inhibition rate of tumor growth was calculated using the formula: (1 - average tumor weight of treated group/average tumor weight of control group) x 100%.

**Immunohistochemical analysis.** At the end of observation (20 days post-inoculation), the xenograft tumors of Maver and Z138 mice were excised and fixed in 10% neutrally buffered formalin for 24 h. After embedded in paraffin, deparaffinized and rehydrated, the histologic sections were subjected to heat-induced epitope retrieval using microwave in 1 mmol/l EDTA buffer (pH 8.0) and quenched for endogenous peroxidase activity with 3% hydrogen peroxide. Then the sections were stained with an rabbit polyclonal antibody to the cell proliferation-associated antigen Ki-67 (1:500 dilution) or a mouse monoclonal antibody to proliferating cell nuclear antigen (PCNA) (1:300 dilution) (Dako Corp., Copenhagen, Denmark), respectively, followed by incubation with the secondary antibody (Dako Corp.) according to the avidin-biotin-peroxidase method. Phosphate-buffered saline (PBS) were used as negative controls. After incubation with 3,3'-diaminobenzidine (DAB) and counterstained with hematoxylin, the sections were analyzed in 5 randomly selected microscopic fields (400x). The Ki-67 labeling index or the positive expression rate of PCNA = (positively stained cells counts / the total number of nucleated cells) x 100%.

**Cell cycle analysis.** The Maver and Z138 cells in each group were collected, washed with PBS and fixed in 70% ethanol overnight at -20°C. The cellular DNA was stained with propidium iodide (PI) (500 µg/ml) (Biosea, China) (10 µl/106 cells) for 10 min at room temperature. The DNA content and cell number were determined by FACS analysis, and the cell cycle profiles were analyzed using the ModFit program (Verify Software House, Inc.). The proliferation index (PI) was calculated using the following equation: PI = [(S+G2M) / (G0/G1+S+G2M)] x 100%. Each experiment was repeated three times.

**Cell migration and invasion assay.** For the in vitro migration and invasion assays, 4x105 or 2x105 cells were resuspended in serum-free medium and placed on the top of an 8-µm pore size Transwell chamber (8.0 µm PC, Corning-Costar, Corning, NY, USA) or Matrigel (1:5 dilution) (BD Biosciences, San Jose, CA, USA) invasion chambers. The lower chambers contained medium with 10% FBS. After 24 h of incubation, the migrating cells in the lower chamber or invading cells on the bottom of each well were stained with 4',6-diamidino-2-phenylindole (DAPI) (1 mg/ml, Solarbio, China) or 0.1% crystal violet following by fixation in methyl alcohol for 30 min, respectively. Then, the number of cells in 6 randomly selected microscopic fields (200x) was counted with a BX51 fluorescence microscope (Olympus, Japan) or a DMIL inverted phase microscope (Leica, German). The migration rate = (cells counts in the lower chamber / total number on the top of Transwell chamber) x 100%. MMP-2 and MMP-9 were detected by RT-PCR to further determine the abilities of tumor cells to penetrate the cell matrix. Each experiment was repeated three times.

**Analysis of drug-induced cytotoxicity and apoptosis.** Rituximab (R, 500, 1,000, 1,500, 2,000, 2,500, 3,000, 3,500 and 4,000 µg/ml) [MabThera, Roche Pharma Ltd., Germany] or bendamustine (Ben, 1, 2, 4, 8, 10, 16, 20 and 40 µg/ml) (Ribomustin, Ribosepharm GmbH, Germany) was added to three groups of Maver and Z138 cells for 24, 48 or 72 h respectively, and then the absorbance was detected using the CCK-8 reagent to evaluate the effects of cell proliferation inhibition by the chemotherapy drugs.

A total of 4x105 Maver cells in each group were grown in triplicate in 6-well plates with 3,500 µg/ml R and/or 4 µg/ml Ben for 12 and 24 h, while the same counts of Z138 cells with 2,500 µg/ml R and/or 4 µg/ml Ben. A volume of 10 µl Annexin V-FITC (20 µg/ml) (Biosea, China) was added to the collected cells. After incubation for 15 min at room temperature, 300 µl binding buffer was added. Then, we added 10 µl PI (50 µg/ml) (Biosea, China) to the mixtures. The cells were examined by flow cytometry within 1 h to determine the cell apoptosis rates induced by the chemotherapy drugs. CellQuest software (Becton-Dickinson) was used for data acquisition and analysis.

**Caspase-3 assay.** The Maver cells (8x106 cells/dish) were treated with 3,500 µg/ml R and/or 4 µg/ml Ben for 0 and 24 h, while the same counts of Z138 cells were treated with 2,500 µg/ml R and/or 4 µg/ml Ben. The cells were then collected and lysed on ice for 1 h. The concentration of protein was detected using the BCA method. A total of 150 µg protein was detected using the caspase-3 Colorimetric Assay kit (Keygen, China). The activity of caspase-3 = OD405 in the experiment group/OD405 in the control group.

**The effect of B7-H3 RNAi on chemosensitivity in vivo.** Mice bearing non-infected Maver and Z138 cell xenografts were allocated randomly into 10 groups respectively (6 mice per group), including: a) an equal volume of NS, b) R (50 mg/kg), c) negative non-targeted control plasmid (pNC) + R, d) short hairpin RNAs targeting B7-H3 plasmid (pKD) + R, e) Ben (25 mg/kg), f) pNC + Ben, g) pKD + Ben, h) R+ Ben, i) pNC + R+ Ben, j) pKD + R + Ben. The treatments began at day 8 and day 10 after inoculation, respectively, for Maver and Z138 mice, when tumors reached an average volume of 100 mm3. The chemotherapy drugs and NS were i.p. administered, while the mixture of plasmid DNA (10 µg) and Lipofectamine 2000 (30 µl; Invitrogen) in 50 µl NS were intratumorally injected. All of the treatments were performed every other day, for a total of three times.

**Statistical analysis.** The data are shown as the mean ± standard deviation (SD) of triplicate values for each experiment. Statistical comparisons were performed using Student's t-test. A value of p<0.05 was considered statistically significant. The statistical analysis was performed using SPSS 18.0 software (Chicago, IL, USA).

**Results**

**B7-H3 stably silences MCL cell line generation.** B7-H3 knockdown in Maver and Z138 cells was performed using lentivirus transduction to stably express shRNA targeting B7-H3. There was no significant difference of B7-H3 expression between the parental non-infection (CON) cells and the transfection negative non-targeted control cells (NC) in each
B7-H3 knockdown inhibits MCL cell migration and invasion. We used Transwell migration and invasion assays to compare the cell migration rate and invasive capacity in each group to determine whether B7-H3 expression affects cell cycle progression. Fig. 3A and B, respectively, show that the Maver and Z138 cell cycle progression was inhibited after B7-H3 silencing. The proliferation index (PI) was decreased by 18.46% in the KD group comparing to the NC group of Maver cells (p=0.002); while it was reduced by 13.49% in B7-H3 knockdown Z138 cells (p=0.034). This suggests that the knockdown of B7-H3 arrests MCL cell cycle at the G0/G1 phase to inhibit cell proliferation.

To evaluate the effects of B7-H3 knockdown on tumor cell proliferation, we used CCK-8 and colony formation assays. The stable knock-down of B7-H3 in Maver and Z138 cells (KD groups) was decreased compared to the relative NC groups (p<0.05). The inhibition rates of mRNA expression in Maver and Z138 cells were 84.5 and 81.2%, whereas the nuclear and cytoplasmic proteins were reduced by 80.3 and 74.5%, and the membrane proteins were the most significantly inhibited by 86.9 and 82.4%, respectively (Fig. 1).

B7-H3 knockdown enhances drug-induced cytotoxicity and apoptosis in vitro. To determine whether B7-H3 knockdown affects drug-induced cytotoxicity and apoptosis, we selected R and Ben, which is increasingly being used for the frontline...
treatment of mantle cell lymphoma (29). Following treatment with various concentrations of R or Ben for 24, 48 or 72 h, a dose-dependent and time-dependent inhibition of cell growth was observed in each group of Maver and Z138 cells using the CCK-8 assay (data not shown). Concentrations of 3,500 µg/ml R and/or 4 µg/ml Ben were treated in Maver cell groups, while 2,500 µg/ml R and/or 4 µg/ml Ben were selected for the Z138 cell groups, and then the absorbance was compared (Fig. 5). The cell survival rates in the KD groups of Maver and Z138 cells were significantly decreased compared with their NC group on day 20.

Figure 2. B7-H3 knockdown inhibits tumor proliferation in vitro and in vivo. (A) B7-H3 silencing inhibited the cell growth analyzed by CCK-8 assay. (B) B7-H3 knockdown inhibited the colony formation detected by methyl cellulose colony forming assay (x100). The data are from at least three separate experiments. (C) Silencing of B7-H3 significantly inhibited tumor growth in vivo compared with the negative non-targeted controls (NC). (D) Excised xenograft tumors on day 20. (E) Immunohistochemical staining of Ki-67 and PCNA for proliferative cells in B7-H3 knockdown xenograft was declined comparing to the NC group on day 20 (x400).
Figure 3. B7-H3 knockdown inhibits cell cycle progression. (A and B) B7-H3 knockdown arrested Maver and Z138 cell cycle at the G0/G1 phase, analyzed by FACS. *Results are statistically significant compared to the NC group, p<0.05. The data are from at least three separate experiments.

Figure 4. B7-H3 knockdown inhibits tumor migration and invasion. (A) B7-H3 knockdown inhibited tumor migration to the lower chamber (x200). (B) B7-H3 knockdown inhibited tumor invasion capacity (x200). (C) Expression of invasion-related proteins MMP-2 and MMP-9 was lower in B7-H3 silenced cells, monitored by RT-PCR analysis. *Results are statistically significant compared to the NC group, p<0.05. The data are from at least three separate experiments.
groups (p<0.05), and these two drug combinations synergistically inhibited MCL cell proliferation.

Exposure to 3,500 µg/ml R and/or 4 µg/ml Ben for 12 and 24 h in Maver cells or 2,500 µg/ml R and/or 4 µg/ml Ben in Z138 cells suggested that B7-H3 silencing promoted apoptosis in a time-dependent manner. The apoptosis rates of shB7-H3/Maver cells in the drug combination groups were 63.84±7.07% for 12 h and 82.43±4.68% for 24 h, which were the most significantly increased (p=0.008 and 0.001). The same conclusion can be drawn for Z138 cells (68.06±7.01% for 12 h and 95.99±3.84% for 24 h) (p=0.006 and 0.002) (Fig. 6A-D). After exposure to R and/or Ben for 24 h, we measured the activity of the apoptosis-related protein caspase-3. The results demonstrated that the activity of caspase-3 in the KD group of Maver cells compared to the NC group was significantly increased (3.32±0.37, 3.36±0.41, and 4.57±0.50 vs. 2.01±0.35, 2.33±0.26, and 2.93±0.61, respectively) (p=0.011, 0.022, and 0.023) (Fig. 6E). Also, the same conclusion can be drawn for Z138 cells (3.45±0.43, 3.79±0.31, and 4.65±0.31 vs. 2.42±0.34, 2.68±0.52 and 3.40±0.35, respectively) (p=0.032, 0.034, and 0.010) (Fig. 6F). These results indicate that silencing B7-H3 increases drug-induced cytotoxicity and promotes drug-mediated apoptosis by increasing the caspase-3 activity in vitro.

**B7-H3 knockdown increases chemosensitivity in xenograft model.** In order to explore the impact of B7-H3 knockdown on the antitumor activity of chemotherapy drugs in vivo, we constructed tumor-bearing mouse models injecting into non-infected Maver and Z138 cells, respectively. The treatments began on day 8 or day 10 in Maver or Z138 xenograft model, when the average tumor volumes reached 100 mm³. As shown in Fig. 6A and E, the plasmids of B7-H3 shRNA (pKD) combined with R and/or Ben were more effective in reducing the established Maver and Z138 tumor growth comparing to the groups of non-targeted control plasmid (pNC) combining chemotherapy, while there were no significant differences in the tumor volumes between the pNC combined with chemotherapy groups and the chemotherapy groups alone. At the end of observation, the inhibition rates of tumor growth were 83.3, 80.9 and 92.3% respectively, which were higher than in the pNC combined with chemotherapy groups with 62.2, 69.5 and 85.4% (p=0.019, 0.049 and 0.043) (Fig. 7B and C). The same conclusion can be drawn for Z138 xenograft model, and the inhibition rates of tumor growth were 83.7, 84.8 and 92.9% vs. 66.8, 64.7 and 82.1% (p=0.030, 0.009 and 0.027) (Fig. 7F and G). Both the Maver and Z138 groups of B7-H3 shRNA combined with two drugs received the best antitumor activity. Besides, all of the mice treated with B7-H3 shRNA exhibited no body weight loss at the end of our experiment (Fig. 7D and H). These results indicate that the B7-H3 silencing can apparently enhance chemosensitivity to mantle cell lymphoma in the xenograft model.

**Discussion.** In the present study, we first generated and confirmed the Maver and Z138 mantle cell lymphoma cells with targeting B7-H3 knockdown using lentivirus transduction. B7-H3 expression abundance was decreased at the mRNA and protein level in both MCL cell lines. The membrane proteins were the most significantly inhibited by 86.9 and 82.4%, respectively. Therefore, the B7-H3 knockdown was specific and efficient, and the MCL cell models may be used for subsequent assays.
Previous studies found that the silencing of B7-H3 did not affect pancreatic (23) and prostate cancer (24) cell proliferation and moderately reduced (20-30%) the growth of melanoma cells (20) in vitro. Interestingly, we found that artificial silencing of B7-H3 significantly inhibited Maver and Z138 cell growth by 41.7 and 37.5% in 72 h, compared with the relative NC groups. After 14 days of culture, the colony-forming ability in these two B7-H3 knockdown cell lines were both inhibited by 71.2 and 77.2%, respectively, in contrast to no significant effect on colony formation performing by B7-H3 silence (30). The different effects of B7-H3 may depend on the various tumor types. Then, we established xenograft models to study the in vivo effect of B7-H3 knockdown in tumorigenicity. The growth of established B7-H3 knockdown Maver and Z138 xenografts slowed down compared with their NC groups by 59.1 and 65.0% at the end of observation, respectively. The similar growth inhibition of B7-H3-knockdown xenografts in glioma (22), breast cancer (26) and pancreatic cancer (23) has been observed in other research. Furthermore, we found that the expressions of Ki-67 and PCNA were significantly decreased in the B7-H3 silenced MCL xenografts. To determine whether B7-H3 knockdown affects the cell cycle, we compared the proliferation index (PI) in shB7-H3/Maver and shB7-H3/Z138 cells with the NC groups, and found that the B7-H3 silencing arrested the cell cycle at the G0/G1 phase. Clearly, the in vivo results confirmed our in vitro observations, and the above findings indicate that B7-H3 knockdown can inhibit the mantle cell lymphoma proliferation through suppressing cell cycle progression and reducing the expression of Ki-67 and PCNA.

Several studies reported that B7-H3 promoted tumor invasion and metastasis in cutaneous melanoma (30), osteosarcoma (25), and non-small cell lung cancer (31). In this study, we found that both the cell migratory and invasive potential in the B7-H3 knockdown groups of Maver and Z138 cells was reduced compared to the NC groups. Since MMP-2 and MMP-9 are proteolytic enzymes involved in tumor cell migration, invasion, and metastasis (32), we measured the mRNA level of both MMPs by RT-PCR and found that the expressions of MMP-2 and MMP-9 were apparently decreased in shB7-H3/Maver and shB7-H3/Z138 cells. Tekle et al also showed a...
similar change of MMP-2 in B7-H3 knockdown melanoma cells (20). It indicates that silencing B7-H3 can impede cell migration and inhibit cell invasion via downregulating the expression of MMP-2 and MMP-9.

In recent years, the prognosis of mantle cell lymphoma has improved likely due to two important factors: the incorporation of high-dose cytarabine in the induction treatment, followed by autologous hematopoietic cell transplantation in first remis-
sion, and the addition of the anti-CD20 monoclonal antibody rituximab (R) to chemotherapy regimens (33). However, the management of relapsed/refractory disease represents a challenge, and a series of novel agents have entered clinical trials. Among these new strategies, bendamustine (Ben), a bifunctional alkylating agent, in combination with rituximab could be recommended as a first-line therapy for MCL (34). In our study, we first observed the cytotoxic effect and apoptosis induced by R and/or Ben in Maver and Z138 cells, and the results confirmed that silencing of B7-H3 increases chemosensitivity in both the single drug and two drug combination groups. The synergistic cell apoptotic effects in Maver and Z138 cells induced by R and Ben were promoted by B7-H3 knockdown in a time-dependent manner. It indicates that B7-H3 knockdown enhances drug-induced cytotoxicity and apoptosis, and a similar conclusion was drawn in B7-H3 silenced breast cancer cells treated with paclitaxel (26). Furthermore, we detected the activity of caspase-3 in Maver and Z138 cells incubated with R and/or Ben for 24 h, which is the mitochondrial downstream effector caspase in apoptosis signaling cascades. It showed that the blockade of B7-H3 significantly increased the caspase-3 activity induced by R and/or Ben in Maver and Z138 cells, compared with their NC groups.

With the development of B7-H3 targeted therapeutics, a range of anti-B7-H3 antibodies are under research and some have entered clinical trial for B7-H3-expressing cancers, such as MGA271 (35). In our study, we treated the Maver and Z138 xenograft models with the plasmid of B7-H3 shRNA combined with R and/or Ben, and found that the inhibition rates of tumor growth were dramatically higher than in the relative non-targeted control plasmid combining chemotherapy groups. At the end of observation, the inhibition rates were even up to 92.3 and 92.9% in the groups of B7-H3 shRNA combined with two drugs in Maver and Z138 mice, respectively. Our findings in vivo demonstrated that the B7-H3 silence apparently enhanced the chemosensitivity of rituximab and bendamustine to mantle cell lymphoma in the xenograft model. Similar promoting effects of B7-H3 on cancer resistance to drug treatments in breast cancer (26) and pancreatic carcinoma (27) xenograft models have been reported.

In this study, we used RNA interference technology to reduce B7-H3 expression in mantle cell lymphoma cells and xenografts, and found that the knockdown of B7-H3 inhibited tumor proliferation, cell cycle progression, migration and invasion. The silencing of B7-H3 increased drug-induced apoptosis and enhanced therapeutic efficacy. Moreover, further investigations should be performed to explore the exact signaling pathways of B7-H3 contributing to oncogenesis and chemoresistance.

Acknowledgements

The authors are very grateful to Dr Chen Huang of Key Laboratory of Peking University Third Hospital for assisting with a preparation of this manuscript. This study was supported by a grant from the National Natural Science Foundation of China (81172245).

References


